• Recruiting

NCT04430894: Phase 2: KRDI in Transplant-Eligible MM

Updated: May 24


NCT04430894: Phase 2: KRDI in Transplant-Eligible MM


KRDI

KRDI in Transplant-Eligible MM


This research study is testing the efficacy of an experimental drug combination for people with newly diagnosed multiple myeloma that are eligible for a stem cell transplant.


The names of the study drugs involved in this study are:

Carfilzomib

Isatuximab

Lenalidomide

Dexamethasone


Sponsor:

Massachusetts General Hospital


Collaborators:

Amgen

Sanofi

 

ClinicalTrials.gov Identifier: NCT04430894


Official Title: A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma


First Posted: June 12, 2020


Click here to see details on ClinicalTrials.gov

 

Drug: Carfilzomib

Drug: Isatuximab

Drug: Lenalidomide

Drug: Dexamethasone

 

Location

United States, Massachusetts




Posts Archive